

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Natural cytotoxicity triggering receptor 1 (NCR1; NKP46)	<p>A study in mice suggests that inhibiting NKP46 could help prevent type 1 diabetes. Streptozotocin-induced type 1 diabetes was lower in <i>Nkp46</i>-deficient mice than in wild-type controls ($p < 0.01$). In a mouse model of diabetes, an <i>Nkp46</i>-Ig fusion protein generated NKP46-specific antibodies that blocked <i>Nkp46</i> signaling and reduced the development of diabetes compared with no treatment ($p < 0.0002$). Next steps include identifying the endogenous ligand for NKP46.</p> <p>SciBX 3(1); doi:10.1038/scibx.2010.13 Published online Jan. 7, 2010</p>	Patent application filed covering use in type 1 diabetes; unavailable for licensing	<p>Gur, C. <i>et al. Nat. Immunol.</i>; published online Dec. 20, 2009; doi:10.1038/ni.1834</p> <p>Contact: Ofer Mandelboim, The Hebrew University of Jerusalem Hadassah Medical School, Jerusalem, Israel e-mail: oferm@ekmd.huji.ac.il</p> <p>Contact: Angel Porgador, Ben-Gurion University of the Negev, Beersheba, Israel e-mail: angel@bgumail.bgu.ac.il</p>